Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14C RPT193 · 1 trial · 1 indication
Amount (in mass equivalents of parent drug) of radioactive drug excreted as TRA in urine and feces
Percent (%) of radioactive drug excreted as TRA in urine and feces
Percent (%) of each drug-related material (parent and each metabolite) in whole blood, plasma, urine and feces
Calculation of area under the curve (AUC) in plasma and urine
| Arm | Type | Description |
|---|---|---|
| 14C RPT193 400 mg | EXPERIMENTAL | Radiolabelled RPT193 |
| Name | Type | Description |
|---|---|---|
| 14C RPT193 | DRUG | Radiolabelled RPT193 |
Inclusion Criteria: * Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to dosing * Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at the screening Exclusion Criteria: * Is mentally or legally incapacitated or has significant emotional pro...
14C RPT193 is a carbon-14 labeled form of RPT193, a small molecule drug candidate developed by RAPT Therapeutics, Inc. (ticker: RAPT). The carbon-14 label is used in clinical pharmacology studies to track how the drug is absorbed, distributed, metabolized, and excreted in the body.
14C RPT193 is being developed by RAPT Therapeutics, Inc., which trades under the ticker symbol RAPT. RAPT Therapeutics is the sponsor of the clinical study evaluating this carbon-14 labeled drug candidate.
14C RPT193 is in Phase 1 clinical development. The single Phase 1 trial, NCT06087978, has been completed. The drug is investigational and has not been approved by the FDA for any indication.
14C RPT193 has been evaluated in one completed Phase 1 clinical trial, NCT06087978, titled "Study of RPT193 in Healthy Adult Male Subjects." The trial enrolled 7 healthy male volunteers in the United States and was an uncontrolled study.
14C RPT193 is used as a radiolabeled tracer in clinical pharmacology research to study the absorption, metabolism, and excretion of RPT193. The specific therapeutic indication for RPT193 has not been disclosed.